Canada - English - Health Canada

hoffmann-la roche limited - saquinavir - capsule - 200mg - saquinavir 200mg - hiv protease inhibitors

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh sandhofer strasse 116 d-68305 mannheim for f. hoffmann-la roche ltd. - epoetin beta - solution for i/v and s/c injection - 2000iu/0,3ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f.hoffmann-la roche ltd. wurmisweg - ceftriaxone (ceftriaxone sodium) - powder for solution for injection - 1000mg

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - solution for injection - tocilizumab 162 mg / 0.9 ml - tocilizumab - - actemra in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (dmards) or tumor necrosis factor (tnf) antagonists. in these patients, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. - actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx - actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (gca) in adult patients. - actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. actemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - mycophenolate mofetil - capsules - 250mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f.hoffmann-la roche ltd. wurmisweg - ceftriaxone (ceftriaxone sodium) - powder for solution for injection for infusion - 1000mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

f.hoffmann-la roche ltd., switzerland - risdiplam - powder for oral solution - 0.75 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

f.hoffmann-la roche ltd., switzerland - pertuzumab,trastuzumab - solution for injection - 80,40 mg/ml,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

f.hoffmann-la roche ltd., switzerland - pertuzumab,trastuzumab - solution for injection - 60,60 mg, µ/ml,

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - faricimab - solution for injection - faricimab 120 mg/ml - faricimab - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with:• neovascular (wet) age-related macular degeneration (namd) • diabetic macular edema (dme)